A comprehensive platform for ex vivo T-cell expansion based on biodegradable polymeric artificial antigen-presenting cells

被引:154
作者
Steenblock, Erin R. [1 ]
Fahmy, Tarek M. [1 ]
机构
[1] Yale Univ, Dept Biomed Engn, New Haven, CT USA
关键词
D O I
10.1038/mt.2008.11
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Efficient T-cell stimulation and proliferation in response to specific antigens is a goal of immunotherapy against infectious disease and cancer. Manipulation of this response can be accomplished by adoptive immunotherapy involving the infusion of antigen-specific T-cell populations expanded ex vivo with antigen presenting cells. We mimicked physiological antigen presentation on a biodegradable microparticle constructed from poly(lactide-co-glycolide) (PLGA), a polymer system whose safety has been established for use in humans. These particles present a high density of adaptor elements for attaching both recognition ligands and co-stimulatory ligands to a biodegradable core encapsulating the cytokine interleukin-2 (IL-2). We demonstrate the utility of this system in efficient polyclonal and antigen-specific T-cell stimulation and expansion, showing that sustained release of IL-2 in the vicinity of T-cell contacts dramatically improves the stimulatory capacity of these acellular systems, as compared to the effect of exogenous addition of cytokine. This results in a 45-fold enhancement in T-cell expansion. In addition, this mode of antigen presentation skews the expansion toward the CD8(+) T-cell phenotype. This comprehensive acellular platform, capable of delivering recognition, costimulatory, and cytokine signals, represents a promising new technology for artificial antigen presentation.
引用
收藏
页码:765 / 772
页数:8
相关论文
共 48 条
[1]   Factors affecting the degradation and drug-release mechanism of poly(lactic acid) and poly[(lactic acid)-co-(glycolic acid)] [J].
Alexis, F .
POLYMER INTERNATIONAL, 2005, 54 (01) :36-46
[2]   Selective stimulation of T cell subsets with antibody-cytokine immune complexes [J].
Boyman, O ;
Kovar, M ;
Rubinstein, MP ;
Surh, CD ;
Sprent, J .
SCIENCE, 2006, 311 (5769) :1924-1927
[3]   CONTROLLED DELIVERY SYSTEMS FOR PROTEINS BASED ON POLY(LACTIC GLYCOLIC ACID) MICROSPHERES [J].
COHEN, S ;
YOSHIOKA, T ;
LUCARELLI, M ;
HWANG, LH ;
LANGER, R .
PHARMACEUTICAL RESEARCH, 1991, 8 (06) :713-720
[4]   B7-1-dependent co-stimulation results in qualitatively and quantitatively different responses by CD4(+) and CD8(+) T cells [J].
Deeths, MJ ;
Mescher, MF .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1997, 27 (03) :598-608
[5]   Adoptive-cell-transfer therapy for the treatment of patients with cancer [J].
Dudley, ME ;
Rosenberg, SA .
NATURE REVIEWS CANCER, 2003, 3 (09) :666-U2
[6]   Surface modification of biodegradable polyesters with fatty acid conjugates for improved drug targeting [J].
Fahmy, TM ;
Samstein, RM ;
Harness, CC ;
Saltzman, WM .
BIOMATERIALS, 2005, 26 (28) :5727-5736
[7]   Increased TCR avidity after T cell activation: A mechanism for sensing low-density antigen [J].
Fahmy, TM ;
Bieler, JG ;
Edidin, M ;
Schneck, JP .
IMMUNITY, 2001, 14 (02) :135-143
[8]   RESULTS OF TREATMENT OF 255 PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA WHO RECEIVED HIGH-DOSE RECOMBINANT INTERLEUKIN-2 THERAPY [J].
FYFE, G ;
FISHER, RI ;
ROSENBERG, SA ;
SZNOL, M ;
PARKINSON, DR ;
LOUIE, AC .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (03) :688-696
[9]   T cells coactivated with immobilized anti-CD3 and anti-CD28 as potential immunotherapy for cancer [J].
Garlie, NK ;
LeFever, AV ;
Siebenlist, RE ;
Levine, BL ;
June, CH ;
Lum, LG .
JOURNAL OF IMMUNOTHERAPY, 1999, 22 (04) :336-345
[10]  
Gattinoni L, 2005, J CLIN INVEST, V115, P1616, DOI 10.1172/JCI24480